JPRN-jRCT2031200240进行中（未招募）3 期
A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis - HERCULES
Tanaka Tomoyuki0 个研究点目标入组 1,290 人开始时间: 2020年12月14日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,290
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 60age old（—）
- 性别
- All
入选标准
- •18 to 60 years of age inclusive
- •- Diagnosis of nonrelapsing secondary progressive multiple sclerosis according to the 2017 McDonald criteria
- •- Expanded disability status scale (EDSS) between 3.0 to 6.5 points inclusive, at screening
- •- The participant must have documented evidence of disability progression observed during the 12 months before screening
- •- Absence of clinical relapses for at least 24 months
- •- Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
- •- A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
- •- Is not a woman of child bearing potential (WOCBP) OR
- •- Is a WOCBP and agrees to use an acceptable contraceptive method
排除标准
- •- The participant has conditions that would adversely affect study participation such as short life expectancy.
- •- History of organ transplant.
- •- Evidence of infection with human immuodeficiency virus (HIV), transplantation, progressive multifocal leukoencephalopathy (PML), active hepatitis B or C, active or latent tuberculosis or other active infections that would adversely affect study participation.
- •- Persistent chronic or active or recurring system infection, that may adversely affect participation or IMP administration in this study, as judged by the Investigator.
- •- History of malignancy within 5 years prior to screening.
- •- History of alcohol or drug abuse within 1 year prior to screening.
- •- Hospitalized for psychiatric disease within 2 years prior to screening.
- •- Clinically significant laboratory abnormalities (including evidence of liver injury) or electrocardiogram abnormalities at screening.
- •- A bleeding disorder, known platelet dysfunctionat any time prior to the screening visit.
- •- A platelet count <150 000/microL at the screening visit.
- •- A history of significant bleeding event within 6 months prior to screening, according to the Investigator's judgment such as, but not limited to cerebral or gastrointestinal bleeding.
- •- Lymphocyte count below the lower limit of normal at screening.
- •- Recent live (attenuated) vaccine within 2 months before the first treatment visit.
- •- Recent major surgery (within 4 weeks of screening) or planned major surgery during the study.
- •- The participant has received medications/treatments for MS within a specified time frame.
- •- Receiving potent and moderate inducers or inhibitors of cytochrome P450 3A (CYP3A) or potent inhibitors of CYP2C8 hepatic enzymes.
- •- Receiving anticoagulant or antiplatelet therapy (such as aspirin >81mg/day , clopidogrel, warfarin).
- •- Contraindications to magnetic resonance imaging (MRI).
- •NOTE: Other Inclusion/Exclusion criteria may apply.
研究者
相似试验
进行中（未招募）
1 期
onrelapsing secondary progressive multiple sclerosis (NRSPMS) study of Bruton tyrosine kinase (BTK) inhibitor tolebrutinib SAR442168 (HERCULES)on-relapsing Secondary Progressive Multiple SclerosisMedDRA version: 21.1Level: PTClassification code 10063400Term: Secondary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-000647-30-PTGenzyme Corporation1,700
进行中（未招募）
1 期
Primary progressive multiple sclerosis (PPMS) Study of Bruton's tyrosine kinase (BTK) inhibitor SAR442168 (PERSEUS)Primary Progressive Multiple SclerosisMedDRA version: 21.1Level: PTClassification code 10063401Term: Primary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-000645-14-HUGenzyme Corporation1,320
进行中（未招募）
1 期
onrelapsing secondary progressive multiple sclerosis (NRSPMS) study of Bruton tyrosine kinase (BTK) inhibitor tolebrutinib SAR442168 (HERCULES)on-relapsing Secondary Progressive Multiple SclerosisMedDRA version: 21.1Level: PTClassification code 10063400Term: Secondary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-000647-30-FIGenzyme Corporation1,700
招募中
1 期
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor tolebrutinib (SAR442168) (PERSEUS)MedDRA version: 21.1Level: PTClassification code: 10063401Term: Primary progressive multiple sclerosis Class: 100000004852Primary Progressive Multiple SclerosisCTIS2024-514495-41-00Genzyme Corp.849
进行中（未招募）
1 期
onrelapsing secondary progressive multiple sclerosis (NRSPMS) study of Bruton tyrosine kinase (BTK) inhibitor SAR442168 (HERCULES)on-relapsing Secondary Progressive Multiple SclerosisMedDRA version: 21.1Level: PTClassification code 10063400Term: Secondary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-000647-30-GBGenzyme Corporation1,700